Saturday 7 November 2026
Export STOK’s income statement to Excel — free account
Stoke Therapeutics, Inc.
STOK Healthcare Biotechnology
Stoke Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $184.4 million, up 404.5% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −65.7%
- Free cash flow
- −114.9%
Quarter to September 2026, against a year earlier
26.54
0.47
+1.80%
Follow STOK
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 3 | 5 |
+8 more TTM periods Free account |
| (73.62%) | (61.10%) | (45.58%) | (2.37%) | ||
| (63.42%) | (53.41%) | (39.94%) | (2.00%) | ||
ROIC |
(482.02%) | (264.77%) | (225.55%) | (18.98%) | |
Return on Tangible Assets |
(77.54%) | (72.84%) | (51.56%) | (2.74%) | |
Average Days of Receivables |
130.37 | 115.36 | 69.87 | 15.65 | |
Free Cash Flow per Share |
(3.16) | (2.74) | (2.34) | 0.76 | |
Free Cash Flow |
(215.72) | (180.68) | (147.69) | 44.92 | |
Capital Expenditures |
(5.41) | (2.69) | (0.87) | (0.67) | |
| Other line items | |||||
Cash ROIC |
(32.11%) | (28.30%) | (20.00%) | 7.05% | |
Accounts Receivable Turnover |
2.70 | 5.34 | 9.51 | 35.90 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
675.98% | 611.01% | 451.74% | 74.79% | |
Selling, General and Administrative Expense of Revenue |
337.15% | 298.68% | 225.71% | 36.38% | |
Share Based Compensation of Revenue |
143.33% | 135.72% | 106.73% | 17.48% | |
Operating CF/Net income |
0.86 | 0.86 | 0.86 | (6.62) | |
Depreciation/Fixed assets |
0.01 | (0.03) | 0.21 | 0.20 | |
Capex/Depreciation |
(44.73) | 17.26 | (1.20) | (1.05) | |
Revenue per Share |
0.41 | 0.42 | 0.51 | 3.11 | |
Operating CF per Share |
(3.08) | (2.70) | (2.33) | 0.77 | |
Capex per Share |
(0.08) | (0.04) | (0.01) | (0.01) | |
Capex to Sales |
0.19 | 0.10 | 0.03 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026